Immunotherapy for Advanced Bladder Cancer
Symposium
Symposium

Immunotherapy for Advanced Bladder Cancer

A Step Forward in Patient Care

Not a member of My prIME? Join now for instant access.

Meeting Overview

Enhance your understanding of the treatment of patients with advanced bladder cancer via a focus on immunotherapy and discussion of the challenges and opportunities that this new therapeutic approach offers. This symposium will conclude with an interactive case-based expert panel discussion, facilitating a better understanding of how this new therapeutic approach can best be integrated into patient care.

This is an official symposium of the ESMO Immuno Oncology Congress 2017.

Date and Location

Saturday, 9 December 2017
13.00 – 14.00

Room A
Palexpo
Route François-Peyrot 30
Geneva, Switzerland

Date/Time

Date/Time

Saturday, 9 December 2017
13.00 – 14.00

Location

Location

Geneva, Switzerland

CME

CME

1.0 AMA PRA Category 1 Credit™

Agenda

13.00 Welcome and introduction
Thomas Powles, MBBS, MRCP, MD
13.02 How much do you know about immunotherapy for bladder cancer?
Thomas Powles, MBBS, MRCP, MD
13.10 The biological basis for checkpoint inhibition in cancer treatment
Aristotle Bamias, MD, PhD
13.22 Q & A
13.25 A giant leap in the treatment options for advanced bladder cancer
Yohann Loriot, MD, PhD
13.40 Q & A
13.45 Interactive case-based panel discussion
13.58 Conclusions and prIME Points™
Thomas Powles, MBBS, MRCP, MD
14.00 Adjourn

Faculty

    Chair

  • Thomas Powles, MBBS, MRCP, MDBarts Cancer Institute
    Queen Mary University of London
    London, United Kingdom
  • Faculty

  • Aristotle Bamias, MD, PhDNational and Kapodistrian University of Athens
    Athens, Greece
  • Yohann Loriot, MD, PhDGustave Roussy
    Villejuif, France

Target Audience

This educational activity is specifically designed to meet the needs of medical oncologists and other healthcare professionals involved in the treatment of patients with urothelial cancers.

Learning Objectives

After successful completion of this educational activity, participants should be able to:

  • Describe the molecular basis for immunotherapy in cancers, including the function of immune checkpoints in the presence and absence of cancers
  • Examine the current evidence of the role of biomarkers and how to apply them in clinical practice
  • Explain the unique patterns of response to immunotherapy
  • Identify immune-related adverse events and strategies to manage them
  • Examine clinical trial findings for immune checkpoint inhibitors in advanced urothelial cancers
  • Describe the rationale for combination therapies of immunotherapeutic agents with each other, with chemotherapy, and with targeted agents

Support

This educational activity is supported by a grant from F. Hoffmann-La Roche Ltd.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

prIME Oncology designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Good CME Practice

Provider

This activity is provided by prIME Oncology.

Sunshine Act/EFPIA

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.

Disclosures

Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.